The side-effects of anti-TNF therapeutics and the failed MS trials can be explained by the pleiotropic, often opposing TNF responses mediated through the two transmembrane TNF receptors, TNF receptor 1 (TNFR1) and TNFR2. The gene discussed is TNFRSF1A; the disease is myeloid sarcoma.